Topical Minoxidil-Loaded Nanotechnology Strategies for Alopecia

Lopedota, 2018, Alginate-Based Hydrogel Containing Minoxidil/Hydroxypropyl-beta-Cyclodextrin Inclusion Complex for Topical Alopecia Treatment, J. Pharm. Sci., 107, 1046, 10.1016/j.xphs.2017.11.016

Adil, 2017, The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis, J. Am. Acad. Dermatol., 77, 136, 10.1016/j.jaad.2017.02.054

Santos, 2015, Drug discovery for alopecia: Gone today, hair tomorrow, Expert Opin. Drug Discov., 10, 269, 10.1517/17460441.2015.1009892

Fang, 2014, Delivery and targeting of nanoparticles into hair follicles, Ther. Deliv., 5, 991, 10.4155/tde.14.61

Tsujimoto, 2007, Evaluation of the permeability of hair growing ingredient encapsulated PLGA nanospheres to hair follicles and their hair growing effects, Bioorg. Med. Chem. Lett., 17, 4771, 10.1016/j.bmcl.2007.06.057

Tricarico, 2018, Characterization of minoxidil/hydroxypropyl-beta-cyclodextrin inclusion complex in aqueous alginate gel useful for alopecia management: Efficacy evaluation in male rat, Eur. J. Pharm. Biopharm., 122, 146, 10.1016/j.ejpb.2017.10.015

Chandrashekar, 2015, Topical minoxidil fortified with finasteride: An account of maintenance of hair density after replacing oral finasteride, Indian Dermatol. Online J., 6, 17, 10.4103/2229-5178.148925

Matos, 2015, Chitosan nanoparticles for targeting and sustaining minoxidil sulphate delivery to hair follicles, Int. J. Biol. Macromol., 75, 225, 10.1016/j.ijbiomac.2015.01.036

Li, 2001, Minoxidil-Induced Hair Growth is Mediated by Adenosine in Cultured Dermal Papilla Cells: Possible Involvement of Sulfonylurea Receptor 2B as a Target of Minoxidil, J. Investig. Dermatol., 117, 1594, 10.1046/j.0022-202x.2001.01570.x

Mali, 2013, Niosomes as a vesicular carrier for topical administration of minoxidil: Formulation and in vitro assessment, Drug Deliv. Transl. Res., 3, 587, 10.1007/s13346-012-0083-1

Lopedota, 2015, New ethanol and propylene glycol free gel formulations containing a minoxidil-methyl-beta-cyclodextrin complex as promising tools for alopecia treatment, Drug Dev. Ind. Pharm., 41, 728, 10.3109/03639045.2014.900078

Vogt, 2016, Nanocarriers for drug delivery into and through the skin—Do existing technologies match clinical challenges?, J. Control. Release, 242, 3, 10.1016/j.jconrel.2016.07.027

Goyal, 2016, Nanoparticles and nanofibers for topical drug delivery, J. Control. Release, 240, 77, 10.1016/j.jconrel.2015.10.049

Sakamoto, K., Lochhead, R., Maibach, H., and Yamashita, Y. (2017). Cosmetic Science and Technology: Theoretical Principles and Applications, Elsevier.

Hadgraft, 2001, Skin, the final frontier, J. Pharm., 224, 1

Benson, H.A.E., and Watkinson, A.C. (2012). Topical and Transdermal Drug Delivery: Principles and Practice, John Wiley & Sons, Inc.

Morales, 2012, Nanocarriers for transdermal drug delivery, Res. Rep. Transdermal. Drug Deliv., 1, 3

Palmer, B.C., and DeLouise, L.A. (2016). Nanoparticle-Enabled Transdermal Drug Delivery Systems for Enhanced Dose Control and Tissue Targeting. Molecules, 21.

Glowka, 2014, Polymeric nanoparticles-embedded organogel for roxithromycin delivery to hair follicles, Eur. J. Pharm. Biopharm., 88, 75, 10.1016/j.ejpb.2014.06.019

Francis, T. (2001). Drug Delivery and Targeting for Pharmacists and Phamaceutical Scientists, Taylor & Francis.

Jayaneththi, 2019, Controlled transdermal drug delivery using a wireless magnetic microneedle patch: Preclinical device development, Sens. Actuators B Chem., 297, 126708, 10.1016/j.snb.2019.126708

Suchonwanit, 2019, Minoxidil and its use in hair disorders: A review, Drug Des. Devel. Ther., 13, 2777, 10.2147/DDDT.S214907

Herrmann, 2017, Methods for the determination of the substantivity of topical formulations, Pharm. Dev. Technol., 22, 487, 10.3109/10837450.2015.1135346

Bibi, N., Ahmed, N., and Khan, G.M. (2017). Nanostructures in Transdermal drug Delivery Systems, Elsevier.

Gupta, 2013, Nanocarriers and nanoparticles for skin care and dermatological treatments, Indian Dermatol. Online J., 4, 267, 10.4103/2229-5178.120635

Benson, H.A.E., Mohammed, Y., Grice, J.E., and Roberts, M.S. (2016). Formulation Effects on Topical Nanoparticle Penetration, Academic Press.

Padois, 2011, Solid lipid nanoparticles suspension versus commercial solutions for dermal delivery of minoxidil, Int. J. Pharm., 416, 300

Wang, 2017, Preparation and Characterization of Minoxidil Loaded Nanostructured Lipid Carriers, AAPS PharmSciTech, 18, 509, 10.1208/s12249-016-0519-x

Uprit, 2013, Preparation and characterization of minoxidil loaded nanostructured lipid carrier gel for effective treatment of alopecia, Saudi Pharm. J., 21, 379, 10.1016/j.jsps.2012.11.005

Silva, 2009, Minoxidil-loaded nanostructured lipid carriers (NLC): Characterization and rheological behaviour of topical formulations, Pharmazie, 64, 177

Gomes, 2014, Lipid nanoparticles for topical and transdermal application for alopecia treatment: Development, physicochemical characterization, and in vitro release and penetration studies, Int. J. Nanomed., 9, 1231

Zhao, 2010, The effects of particle properties on nanoparticle drug retention and release in dynamic minoxidil foams, Int. J. Pharm., 383, 277, 10.1016/j.ijpharm.2009.09.029

Aljuffali, 2014, Squarticles as a lipid nanocarrier for delivering diphencyprone and minoxidil to hair follicles and human dermal papilla cells, AAPS J., 16, 140, 10.1208/s12248-013-9550-y

Aljuffali, 2015, Anti-PDGF receptor beta antibody-conjugated squarticles loaded with minoxidil for alopecia treatment by targeting hair follicles and dermal papilla cells, Nanomedicine, 11, 1321, 10.1016/j.nano.2015.04.009

Mura, 2007, Liposomes and niosomes as potential carriers for dermal delivery of minoxidil, J. Drug Target., 15, 101, 10.1080/10611860600991993

Mura, 2009, Penetration enhancer-containing vesicles (PEVs) as carriers for cutaneous delivery of minoxidil, Int. J. Pharm., 380, 72, 10.1016/j.ijpharm.2009.06.040

Rabasco, 2005, Effect of cholesterol and ethanol on dermal delivery from DPPC liposomes, Int. J. Pharm., 298, 1, 10.1016/j.ijpharm.2005.02.021

Hasanovic, 2010, Improvement in physicochemical parameters of DPPC liposomes and increase in skin permeation of aciclovir and minoxidil by the addition of cationic polymers, Eur. J. Pharm. Biopharm., 75, 148, 10.1016/j.ejpb.2010.03.014

Balakrishnan, 2009, Formulation and in vitro assessment of minoxidil niosomes for enhanced skin delivery, Int. J. Pharm., 377, 1, 10.1016/j.ijpharm.2009.04.020

Touitou, 2000, Ethosomes—Novel vesicular carriers for enhanced delivery: Characterization and skin penetration properties, J. Control. Release, 65, 403, 10.1016/S0168-3659(99)00222-9

Ying, 2007, Effect of ethosomal minoxidil on dermal delivery and hair cycle of C57BL/6 mice, J. Dermatol. Sci., 45, 135, 10.1016/j.jdermsci.2006.09.007

Ramezani, 2018, Formulation and optimization of transfersome containing minoxidil and caffeine, J. Drug Deliv. Sci. Technol., 44, 129, 10.1016/j.jddst.2017.12.003

Shim, 2004, Transdermal delivery of mixnoxidil with block copolymer nanoparticles, J. Control. Release, 97, 477, 10.1016/S0168-3659(04)00167-1

Takeuchi, 2018, Minoxidil-encapsulated poly(L-lactide-co-glycolide) nanoparticles with hair follicle delivery properties prepared using W/O/W solvent evaporation and sonication, Biomed. Mater. Eng., 29, 217

Nagai, 2019, Drug Delivery System Based On Minoxidil Nanoparticles Promotes Hair Growth In C57BL/6 Mice, Int. J. Nanomed., 14, 7921, 10.2147/IJN.S225496

Kwon, 2010, In vitro skin permeation of monoolein nanoparticles containing hydroxypropyl beta-cyclodextrin/minoxidil complex, Int. J. Pharm., 392, 268, 10.1016/j.ijpharm.2010.03.049

Garces, 2018, Formulations based on solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for cutaneous use: A review, Eur. J. Pharm. Sci., 112, 159, 10.1016/j.ejps.2017.11.023

Roberts, 2017, Topical and cutaneous delivery using nanosystems, J. Control. Release, 247, 86, 10.1016/j.jconrel.2016.12.022

Shegokar, 2011, 20 Years of Lipid Nanoparticles (SLN & NLC): Present State of Development & Industrial Applications, Curr. Drug Discov. Technol., 8, 207, 10.2174/157016311796799062

Charoenputtakun, 2014, Terpene Composited Lipid Nanoparticles for Enhanced Dermal Delivery of All-trans-Retinoic Acids, Biol. Pharm. Bull., 37, 1139, 10.1248/bpb.b14-00015

Carter, 2019, Biocompatible nanoparticles and vesicular systems in transdermal drug delivery for various skin diseases, Int. J. Pharm., 555, 49, 10.1016/j.ijpharm.2018.11.032

Muller, 2007, Nanostructured lipid carriers (NLC) in cosmetic dermal products, Adv. Drug Deliv. Rev., 59, 522, 10.1016/j.addr.2007.04.012

Souto, 2020, SLN and NLC for topical, dermal, and transdermal drug delivery, Expert Opin. Drug Deliv., 17, 357, 10.1080/17425247.2020.1727883

Modi, 2012, Transfersomes: New Dominants for Transdermal Drug Delivery, Am. J. Pharm. Tech. Res., 2, 71

Muzzalupo, 2011, A new approach for the evaluation of niosomes as effective transdermal drug delivery systems, Eur. J. Pharm. Biopharm., 79, 28, 10.1016/j.ejpb.2011.01.020

Choi, 2005, Liposomes and niosomes as topical drug delivery systems, Skin Pharmacol. Physiol., 18, 209, 10.1159/000086666

Try, 2014, Nanomedicine strategies for targeting skin inflamation, Nanomedicine, 9, 1727, 10.2217/nnm.14.74

Barua, 2014, Challenges associated with Penetration of Nanoparticles across Cell and Tissue Barriers: A Review of Current Status and Future Prospects, Nano Today, 9, 223, 10.1016/j.nantod.2014.04.008

Bakowsky, 2008, Adhesion characteristics and stability assessment of lectin-modified liposomes for site-specific drug delivery, Biochim. Biophys. Acta, 1778, 242, 10.1016/j.bbamem.2007.09.033

Toshimitsu, 1994, Vesicle (niosome)-in-water-in-oil (v/w/o) emulsions: An in vitro study, Int. J. Pharm., 1018, 117, 10.1016/0378-5173(94)90322-0

Bhardwaj, 2020, Niosomes: A review on niosomal research in the last decade, J. Drug Deliv. Sci. Technol., 56, 101581, 10.1016/j.jddst.2020.101581

Moghassemi, 2014, Nano-niosomes as nanoscale drug delivery systems: An illustrated review, J. Control. Release, 185, 22, 10.1016/j.jconrel.2014.04.015

Uchechi, 2014, Nanoparticles for Dermal and Transdermal Drug Delivery, Appl. Nanotechnol. Drug Deliv., 4, 193

Rajera, 2011, Niosomes: A Controlled and Novel Drug Delivery System, Biol. Pharm. Bull., 34, 945, 10.1248/bpb.34.945

Touitou, 2000, Enhanced Delivery of Drugs Into and Across the Skin by Ethosomal Carriers, Drug Dev. Res., 50, 406, 10.1002/1098-2299(200007/08)50:3/4<406::AID-DDR23>3.0.CO;2-M

Hua, 2015, Lipid-based nano-delivery systems for skin delivery of drugs and bioactives, Front. Pharmacol., 6, 219, 10.3389/fphar.2015.00219

Rajan, 2011, Transferosomes—A vesicular transdermal delivery system for enhanced drug permeation, J. Adv. Pharm. Technol. Res., 2, 138, 10.4103/2231-4040.85524

Jain, 2017, Recent Advances in Lipid-Based Vesicles and Particulate Carriers for Topical and Transdermal Application, J. Pharm. Sci., 106, 423, 10.1016/j.xphs.2016.10.001

Karami, 2016, Cubosomes: Remarkable drug delivery potential, Drug Discov. Today, 21, 789, 10.1016/j.drudis.2016.01.004

Pan, 2013, Nanostructured cubosomes as advanced drug delivery system, Curr. Pharm. Des., 19, 6290, 10.2174/1381612811319350006

Naik, 2004, Skin penetration and distribution of polymeric nanoparticles, J. Control. Release, 99, 53, 10.1016/j.jconrel.2004.06.015

Li, 2017, Nanosystem trends in drug delivery using quality-by-design concept, J. Control. Release, 256, 9, 10.1016/j.jconrel.2017.04.019

Ramezanli, 2017, Polymeric nanospheres for topical delivery of vitamin D3, Int. J. Pharm., 516, 196, 10.1016/j.ijpharm.2016.10.072

Zhao, D., Yu, S., Sun, B., Gao, S., Guo, S., and Zhao, K. (2018). Biomedical Applications of Chitosan and Its Derivative Nanoparticles. Polymers (Basel), 10.

Hu, 2011, Rheological behaviour of chitin in NaOH/urea aqueous solution, Carbohydr. Polym., 83, 1128, 10.1016/j.carbpol.2010.09.014

Gutha, 2017, Antibacterial and wound healing properties of chitosan/poly(vinyl alcohol)/zinc oxide beads (CS/PVA/ZnO), Int. J. Biol. Macromol., 103, 234, 10.1016/j.ijbiomac.2017.05.020

Zhang, 2013, Polymeric nanoparticles-based topical delivery systems for the treatment of dermatological diseases, Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol., 5, 205, 10.1002/wnan.1211

Borowska, 2015, Metals in cosmetics: Implications for human health, J. Appl. Toxicol., 35, 551, 10.1002/jat.3129

Arora, 2012, Latest Technology Advances in Cosmaceuticals, Int. J. Pharm. Sci. Drug Res., 4, 168

Bilensoy, E. (2011). Cyclodextrins in the Cosmetic Field, in Cyclodextrins in Pharmaceutics, Cosmetics, and Biomedicine: Current and Future Industrial Applications, John Wiley & Sons, Inc.

Isigonis, P., Hristozov, D., Benighaus, C., Giubilato, E., Grieger, K., Pizzol, L., Semenzin, E., Linkov, I., Zabeo, A., and Marcomini, A. (2019). Risk Governance of Nanomaterials: Review of Criteria and Tools for Risk Communication, Evaluation, and Mitigation. Nanomaterials (Basel), 9.

Gupta, 2012, Nanocarrier-based topical drug delivery for the treatment of skin diseases, Expert Opin. Drug Deliv., 9, 783, 10.1517/17425247.2012.686490

Nel, 2006, Toxic potential of materials at the nanolevel, Science, 311, 622, 10.1126/science.1114397

Inman, 2009, Limitations and relative utility of screening assays to assess engineered nanoparticle toxicity in a human cell line, Toxicol. Appl. Pharmacol., 234, 222, 10.1016/j.taap.2008.09.030

Pourmand, 2012, Current Opinion on Nanotoxicolog, Daru, 20, 95, 10.1186/2008-2231-20-95

Bahadar, 2016, Toxicity of Nanoparticles and an Overview of Current Experimental Models, Iran. Biomed. J., 20, 1

Wang, 2014, Application of nanotechnology in improving bioavailability and bioactivity of diet-derived phytochemicals, J. Nutr. Biochem., 25, 363, 10.1016/j.jnutbio.2013.10.002

Yuan, 2014, Study on characteristics and harm of surfactants, J. Chem. Pharm. Res., 6, 2233

Moustafalou, 2013, Different biokinetics of nanomedicines linking to their toxicity; an overview, DARU J. Pharm. Sci., 21, 14, 10.1186/2008-2231-21-14

Duncan, 2011, Nanomedicine(s) under the microscope, Mol. Pharm., 8, 2101, 10.1021/mp200394t

International Organization for Standardization (2019, November 21). ISO/TS 13830:2013—Guidance on Voluntary Labelling for Consumer Products Containing Manufactured Nano-Objects. Available online: https://www.iso.org/standard/54315.html.

International Organization for Standardization (2019, November 21). ISO 19007:2018—In vitro MTS Assay for Measuring the Cytotoxic Effect of Nanoparticles. Available online: https://www.iso.org/standard/63698.html.

U. S. Food and Drug Administration (2017). Drug Products, Including Biological Products, that Contain Nanomaterials—Draft Guidance for Industry, Office of Medical Products and Tobacco.

Hofmann, 2014, Nanotechnology in medicine: European research and its implications, Swiss Med. Wkly., 144, w14044

Kelly, B. (2010). Nanomedicines: Regulatory Challenges and Risks Ahead, Regulatory Affairs Pharma.

European Medicines Agency (2019, November 21). European Medicines Agency’s Workshop on Nanomedicines. Available online: https://www.ema.europa.eu/en/events/european-medicines-agencys-workshop-nanomedicines.

Beer, C. (2016). Nanotoxicology and Regulatory Affairs, Springer.

Patravale, V., Dandekar, P., and Jain, R. (2012). Regulatory Aspects of Nanoparticulate Drug Delivery Systems, Elsevier.

European Parliament (2020, March 27). EU Directive 2001/83/EC—Community Code Relating to Medicinal Products for human Use. Available online: https://eur-lex.europa.eu/legal-content/en/ALL/?uri=CELEX%3A32001L0083.

European Council (2020, March 27). EU Directive 93/42/EEC—Concerning Medical Devices. Available online: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A31993L0042.